Concordia Healthcare Corp. T.CXR.R

So you think CXR paid too much for their drug rights?

[MirrorWorldMan]

I cannot think of a BP in the past that has not paid too much for a drug, or co-licensing agreement, or co-promotion contract,  or process & development acquisition,  or BioTech company. It's pretty common occurrence, and guess what? All those companies are still around and flourishing after the setback. Pharma companies drop or cancel formal  agreements all the time if market realities turn out different than expected. Nothing new here. CXR will be fine.

[Craigbad]

The problem is they paid a premium for drugs which had competition coming through the fda pipeline. The information was readily available and is a complete lack of DD when your spending the kind of money they did. This resulted in a huge writedown, reduced cashflow, but the debt is still there and makes it a very burden given the leverage. Analysts have indicated there is more competition coming

[PROtrading]

CORRECT!!! WAY OVERPAID!  Like 1/3 of it is "goodwill" which is "brand name".  Well, that's fine and dandy if the pipeline was strong and the legacy drugs were strong but neither of them are! There is no pipeline.  This is not a pharma play, it's a merger and acquisition/street play! There is near zero R&D, the stuff that costs pharma a TON OF